Effects of Paricalcitol and Aliskiren Combination Therapy on Experimental Diabetic Nephropathy Model in Rats | Zendy

Eren Zehra | Zendy; Günal Mehmet Yalçin | Zendy; Bakir Elif Arı | Zendy; Coban Jale | Zendy; Çağlayan Berrak | Zendy; Ekimci Nur | Zendy; Ethemoglu Sinem | Zendy; Albayrak Ozgur | Zendy; Akdeniz Tuba | Zendy; Demirel Gülderen Yanikkaya | Zendy; Kiliç Ertuğrul | Zendy; Kantarci Gülçin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of Paricalcitol and Aliskiren Combination Therapy on Experimental Diabetic Nephropathy Model in Rats

Author(s) -

Eren Zehra,

Günal Mehmet Yalçin,

Bakir Elif Arı,

Coban Jale,

Çağlayan Berrak,

Ekimci Nur,

Ethemoglu Sinem,

Albayrak Ozgur,

Akdeniz Tuba,

Demirel Gülderen Yanikkaya,

Kiliç Ertuğrul,

Kantarci Gülçin

Publication year - 2014

Publication title -

kidney and blood pressure research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.806

H-Index - 51

eISSN - 1423-0143

pISSN - 1420-4096

DOI - 10.1159/000368471

Subject(s) - original paper

Background/Aims: The aim of the present study was to investigate the effect of combination of aliskiren with paricalcitol on experimental diabetic nephropathy (DN) model in rats. Methods: Forty male Sprague Dawley rats were divided into 5 groups of 8 rats each, namely the control (Group C), diabetes (Group D), aliskiren (Group A), paricalcitol (Group P), and aliskiren plus paricalcitol (Group A+P) groups. Aliskiren was given by oral-gavage at a dose of 50 mg/kg/day once daily for 12 weeks. Paricalcitol was given by intraperitoneally at a dose of 0,4 µg/kg/three day of week for 12 weeks. Renal function parameters, oxidative stress biomarkers, mRNA expression of renin-angiotensin system parameters and kidney histology were determined. Results: Group A+P had lower mean albümin-to-creatinine ratio (ACR) (p=0.004) as well as higher creatinine clearance (CCr) (p<0.005) than the diabetic rats (Group D). Combination therapy significantly increased CCr (Group A+P vs Group A, p<0.005; Group A+P vs Group P, p=0.022) and reduced ACR (Group A+P vs Group A, p=0.018; Group A+P vs Group P, p<0.005) when compared to monotherapy. Serum malondialdehyde levels were significantly lower (p=0.004); glutathion levels (p=0.003), glutathion peroxidase (p=0.004) and superoxide dismutase (p<0.005) activities were significantly higher in group A+P than in group D. The mean scores of mRNA expression of renin (p<0.005), angiotensin II (p=0.012) and angiotensin type 1 receptor (p=0.018) in group A+P were significantly lower. Although combination therapy showed no additional effect on oxidative system, renin-angiotensin system and renal histology, aliskiren plus paricalcitol significantly decreased interstitial fibrosis volume when compared to monotherapy (Group A+P vs Group A, p<0.005; Group A+P vs Group P, p=0.002). Conclusion: Our data seem to suggest a potential role of aliskiren plus paricalcitol acting synergystically for reducing the progression of diabetic nephropathy in an experimental rat model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research